Coronavirus disease 2019 \[COVID-19\], caused by infection with severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\], is rapidly spreading as a global pandemic. Because the severe pneumonia induced by COVID-19 has a high fatality rate, there is an urgent need to develop efficacious treatments. It is suggested that severe COVID-19 is induced via cytokine storms, and some cytokine blockers may prevent COVID-19-driven pneumonia.^[@CIT0001]^

Tursi *et al*. reported a Crohn's disease patient who developed only mild COVID-19-driven pneumonia under treatment with adalimumab.^[@CIT0002]^ Here, we report a similar development in an older, more intensively immunosuppressed patient, who was infected with SARS-CoV-2 but did not develop pneumonia despite anti-tumour necrosis factor alpha \[TNF-α\] antibody treatment.

A man in his late 60s embarked on a cruise ship with his wife and mother-in-law. He had been treated with infliximab \[5 mg/kg/8-weekly\] together with azathioprine and high-dose oral mesalazine for refractory ulcerative colitis. He had been well for several years and received his latest infusion of infliximab 4 days before boarding.

On the cruise ship, he developed cough and high fever, and polymerase chain reaction \[PCR\] analysis confirmed SARS-CoV-2 positivity. He was soon transported to our hospital for suspected COVID-19-driven pneumonia, but no findings of pneumonia were observed on chest computed tomography \[CT\]. His symptoms resolved within a few days without special treatment.

His wife and mother-in-law, who were sharing the same cabin space, also became infected with SARS-CoV-2. His mother-in-law, who was in her late 80s and was taking angina pectoris treatment and methotrexate for rheumatoid arthritis, did not develop pneumonia. However, his wife, who was the youngest family member and was undergoing angina pectoris treatment but was not receiving immunosuppressive medication, developed COVID-19-driven pneumonia.

It would seem that patients with inflammatory bowel disease \[IBD\] could be at high risk of COVID-19, because the inflamed gut represents an optimal route of entry for SARS-CoV-2, based on its enhanced expression of angiotensin-converting enzyme 2 \[ACE2\], the binding receptor for SARS-CoV-2.^[@CIT0003]^ However, despite many patients receiving immunosuppressive therapies, there is no evidence that IBD patients have an increased risk of COVID-19 or of developing severe disease.^[@CIT0004]^ Interleukin \[IL\]-2R, IL-6, and TNFα are highly expressed in severe COVID-19 patients, and Feldmann *et al*. proposed the need for clinical trials of anti-TNFα therapy for COVID-19.^[@CIT0005]^ Notably, there have been recent reports of paediatric patients who developed Kawasaki disease following COVID-19, and infliximab among biologics has a therapeutic effect on Kawasaki disease. Tursi *et al.* and Allocca *et al*. also suggested the potential preventative effect of anti-TNFα antibodies on COVID-19-driven pneumonia. Taken together with our elderly cases, we speculate that anti-TNFα antibodies may inhibit COVID-19-driven pneumonia, although this hypothesis must be confirmed by large epidemiological studies and the currently ongoing clinical trials.
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